Unlock instant, AI-driven research and patent intelligence for your innovation.

Crystallization of Cyclic Amine Derivatives and Its Medical Application

A technology of crystallization and medicine, applied in the field of crystallization of cyclic amine derivatives, can solve the problem of low therapeutic effect

Active Publication Date: 2021-05-11
TORAY IND INC
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, NSAIDs and opioids are generally considered to have low therapeutic effects (Non-Patent Document 1)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Crystallization of Cyclic Amine Derivatives and Its Medical Application
  • Crystallization of Cyclic Amine Derivatives and Its Medical Application
  • Crystallization of Cyclic Amine Derivatives and Its Medical Application

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0107] Preparations of the above-mentioned dosage forms can be carried out according to known production methods generally used in the field of pharmaceutical preparations. At this time, if necessary, for example, excipients, binders, lubricants, disintegrants, sweeteners, surfactants, suspending agents or emulsifiers generally used in the field of formulations can be contained and produced.

[0108] Tablets can be prepared with, for example, excipients, binders, disintegrants or lubricants, and pills and granules can be prepared with, for example, excipients, binders or disintegrants. In addition, powders and capsules can be prepared containing, for example, excipients, syrups can be prepared containing, for example, sweeteners, and emulsions or suspensions can be prepared containing, for example, surfactants, suspending agents or emulsifying agents. And proceed.

[0109] Examples of excipients include lactose, glucose, starch, sucrose, microcrystalline cellulose, licorice pow...

Embodiment

[0121] The following examples are given to describe the present invention in detail, but the present invention is not limited to these examples.

[0122] Compound (I) and the raw materials and intermediates of compound (I) were synthesized by the methods described in the following Reference Examples. In addition, the commercially available compound was used for the compound used for the synthesis|combination of the reference example compound whose synthesis method is not described.

[0123] In the following description, the name of the solvent shown in the NMR data is the solvent used for the measurement. Also, the 400 MHz NMR spectrum was measured using a JNM-AL400 nuclear magnetic resonance apparatus (manufactured by JEOL Ltd.). The chemical shifts are based on tetramethylsilane, expressed in δ (unit: ppm), and the signals are expressed in s (singlet), d (doublet), t (triplet), q (quartet), quint (quintuplet) doublet), sept (septet), m (multiplet), br (broad), dd (double d...

reference example 1

[0124] (Reference Example 1) Preparation of the amorphous body of compound (I):

[0125] To 1-(4-(dimethylamino)piperidin-1-yl)-3-(1-methyl-1H-imidazol-2-yl)propane-1,3-dione (3.0g, 10.8mmol ) in isopropanol (90mL) solution in nitrogen atmosphere, add chloro[(S,S)-N-[2-[2-(4methylbenzyloxy)ethyl]amino-1,2-diphenyl Ethyl]-p-toluenesulfonamide]ruthenium(II) catalyst (175mg, 0.263mmol), and stirred at an internal temperature of 80°C for 18 hours. The reaction solution was concentrated, and 42.8 g of distilled water was transferred to a separatory funnel. After extraction with ethyl acetate, the ethyl acetate layer was extracted with distilled water, and all aqueous layers were combined and concentrated. After concentration, ethyl acetate was added, and azeotropic dehydration was performed with an evaporator. The residue was substituted with chloroform, and the concentrate was purified by silica gel column chromatography (NH silica gel, chloroform). Drying under reduced pressu...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
wavelengthaaaaaaaaaa
Login to View More

Abstract

An object of the present invention is to provide a pharmaceutically useful crystal of a compound exhibiting an analgesic effect on neuropathic pain and / or fibromyalgia. The present invention provides (S)-1-(4-(dimethylamino)piperidin-1-yl)-3-hydroxyl-3-(1-methyl-1H-imidazol-2-yl)propane-1- Crystals of ketones or their pharmacologically acceptable salts.

Description

technical field [0001] The present invention relates to the crystallization of cyclic amine derivatives and their medical application. Background technique [0002] Pain is an experience accompanied by unpleasant sensations and unpleasant emotions that occurs when tissue is damaged or there is a possibility of such damage. Pain is mainly classified according to its cause as nociceptive pain, neuropathic pain or psychopathic pain. In addition, fibromyalgia is known as pain of unknown origin. [0003] Neuropathic pain is morbid pain caused by abnormal function of the peripheral or central nervous system itself. It is the pain caused by direct injury and compression of nerve tissue without receiving noxious stimulation by nociceptors. As a therapeutic drug for neuropathic pain, an anticonvulsant, an antidepressant, an anxiolytic, or an antiepileptic drug such as gabapentin or pregabalin is used. [0004] Fibromyalgia is a disease in which general pain is the main symptom, an...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D401/06A61K31/454A61P21/00A61P25/04
CPCA61K31/454C07D401/06A61P25/04A61P21/00A61P29/00C07B2200/13
Inventor 高桥弘纯马场萌子盛田康弘伊关克彦泉本直树
Owner TORAY IND INC